Skip to Main Navigation

Third Additional Financing for the Ethiopia COVID-19 Emergency Response Project

Abstract*

The third AF will support investments to bring immunization systems and service delivery capacity to the level required to successfully deliver COVID-19 vaccines at scale, through all the 5 Components of the parent project. Component 1: Medical Supplies and Equipment [proposed AF3 allocation US$41.0 million equivalent] Under this component, AF3 will finance: (i) the procurement of COVID-19 vaccine doses to cover an additional 10 percent of the population;...

* The project abstract is drawn from the PAD, SAR or PGD and may not accurately reflect the project's current nature

Show More

Development Objective

To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Ethiopia.

Key Details

Project Details

  • P178821

  • Active

  • Enias Baganizi , Roman Tesfaye

  • Democratic Republic of Ethiopia

  • Ethiopia

  • April 29, 2022

  • (as of board presentation)

    May 31, 2022

  • N/A

  • US$ 195.00 million

  • N/A

  • N/A

  • December 31, 2025

  • Yes

  • BANK APPROVED

  • P173750

  • September 8, 2023

  • Notes

Finances

Financing Plan (US$ Millions)

No data available.
Financier Commitments
IDA Grant 195.00

Total Project Financing (US$ Millions)

Product Line IBRD/IDA
IBRD Commitment N/A
IDA Commitment 195.00
IBRD + IDA Commitment 195.00
Lending Instrument
Grant Amount N/A
Total Project Cost** 195.00

Summary Status of World Bank Financing (US$ Millions) as of March 31, 2025

Download:
No data available.
Financier Approval Date Closing Date Principal Disbursed Repayments Interest, Charges & Fees

Detailed Financial Activity as of March 31, 2025

Download:
No data available.
Period Financier Transaction Type Amount (US$)

Footnotes

Ratings

IMPLEMENTATION RATINGS

No data available.

COMPLETION RATINGS

No data available.

INDEPENDENT EVALUATION RATINGS

No data available.

Results Framework

No data available.